Human isoleucyl-tRNA synthetase proteins, nucleic acids and tester strains comprising same
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 2, 1998
Issued Date -
N/A
app pub date -
Jun 6, 1995
filing date -
May 27, 1994
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Isolated, recombinant nucleic acids which encode an isoleucyl-tRNA synthetase (IleRS) of human origin have been used to make expression constructs and transformed host cells for the production of a recombinant human IleRS. A recombinant enzyme has been purified, and is active in the specific aminoacylation of tRNA by isoleucine. Isolated, recombinant enzyme, and antibodies made specifically thereto, can be useful in assays to diagnose and monitor the autoimmune disease known as 'antisynthetase syndrome.' The essential isoleucyl-tRNA synthetases of microbes pathogenic in humans can be the targets of inhibitory agents having antimicrobial activity. A human isoleucyl-tRNA synthetase, isolated and purified, can be used to assess the toxic effect in humans of such an inhibitory agent in various biochemical activity assays. This human enzyme can also be expressed in 'tester strains,' whose cells rely upon the function of the human isoleucyl-tRNA synthetase for tRNA.sup.Ile charging. Such tester strains can be used to test for any toxic effects of an antimicrobial agent that specifically interacts with a heterologous human IleRS gene or gene product.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully